Drug Type Small molecule drug |
Synonyms DPPE, N,N-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine, Tesmilifene + [4] |
Target |
Action antagonists |
Mechanism ERs antagonists(Estrogen receptors antagonists), Histamine receptor antagonists |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC19H26ClNO |
InChIKeyTXLHNFOLHRXMAU-UHFFFAOYSA-N |
CAS Registry92981-78-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic breast cancer | Phase 1 | United Kingdom | 01 May 2004 | |
Neoplasm Metastasis | Phase 1 | United Kingdom | 01 May 2004 | |
Hepatocellular Carcinoma | Phase 1 | - | - | |
Prostatic Cancer | Phase 1 | Canada | - | - |
Prostatic Cancer | Phase 1 | United States | - | - |
Stomach Cancer | Phase 1 | - | - | |
Breast Cancer | Preclinical | Canada | 01 May 2007 | |
Squamous Cell Carcinoma of Head and Neck | Preclinical | Canada | 01 May 2007 |